A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

Phase 2CompletedNCT02241772

Xention Ltd42 enrolled

Overview

A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Elevated Lp(a)

Interventions

TA-8995DRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female (of non-child bearing potential) subjects with elevated Lp(a) levels Exclusion Criteria: * Clinically significant medical history * Abnormal laboratory results (other than lipid levels) or vital signs * Receiving any other drug therapy

Locations (1)

Herlev Hospital

Herlev, Denmark

Outcomes

Primary Outcomes

To evaluate the change from baseline in (Lp(a) levels after 12 weeks of treatment with TA-8995.

Time frame: 12 weeks

Secondary Outcomes

Number of participants with adverse events

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.